Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Clinical and Research Reports   |    
Treatment of Depression in a Former Smoker With Varenicline? A Case Report and Discussion
Otto Kausch, M.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;26:172-175. doi:10.1176/appi.neuropsych.13030045
View Author and Article Information

The author reports no financial relationships with commercial interests.

From the Mental Health Clinic, Southern Arizona Veterans Administration Health Care System, Tucson, AZ.

Send correspondence to Dr. Kausch: e-mail: otto.kausch@va.gov

Copyright © 2014 by the American Psychiatric Association

Received March 05, 2013; Accepted July 15, 2013.


The U.S. Food and Drug Administration has warned that patients being treated for smoking cessation with varenicline may develop depression. A case of successful treatment for depression with varenicline is described. The patient’s depression recurred several times with inadvertent varenicline discontinuation, then remitted again after resuming varenicline. The literature supporting the potential use of varenicline for depression is reviewed.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).



Moore TJ, Furberg CD, Glenmullen J, et al: Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011; 6:e27016
Trivedi  MH;  Rush  AJ;  Wisniewski  SR  et al; STAR*D Study Team:  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.  Am J Psychiatry 2006; 163:28–40
[CrossRef] | [PubMed]
Gonzales  D;  Rennard  SI;  Nides  M  et al; Varenicline Phase 3 Study Group:  Vareniclicline, an alpha4beta2 nicontinic acetylcholine partial agonist vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.  JAMA 2006; 296:47–55
[CrossRef] | [PubMed]
Philip  NS;  Carpenter  LL;  Tyrka  AR  et al:  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.  Psychopharmacology (Berl) 2010; 212:1–12
[CrossRef] | [PubMed]
Patterson  F;  Jepson  C;  Strasser  AA  et al:  Varenicline improves mood and cognition during smoking abstinence.  Biol Psychiatry 2009; 65:144–149
[CrossRef] | [PubMed]
Philip  NS;  Carpenter  LL;  Tyrka  AR  et al:  Varenicline augmentation in depressed smokers: an 8-week, open-label study.  J Clin Psychiatry 2009; 70:1026–1031
[CrossRef] | [PubMed]
Blum  K;  Bailey  J;  Gonzalez  AM  et al:  Neuro-genetics of reward deficiency syndrome (RDS) as the root cause of “addiction transfer”: a new phenomenon common after bariatric surgery.  J Genet Syndromes Gene Ther 2011; S2:001.
Murphy  S:  The people who are addicted to addiction.  New Sci 2012; 2881:36–39
Blum  K;  Sheridan  PJ;  Wood  RC  et al:  The D2 dopamine receptor gene as a determinant of reward deficiency syndrome.  J R Soc Med 1996; 89:396–400
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 15.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 58.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 16.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 15.  >
APA Practice Guidelines > Chapter 15.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles